(Q46194250)

20 December 2017

title

HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors (English)

1 reference

20 December 2017

0 references

0 references

0 references

Kenzo Tokunaga

12

0 references

David Ofori-Adjei

object named as

David Ofori-Adjei

8

0 references

Françoise Barré-Sinoussi

10

object named as

Françoise Barre-Sinoussi

1 reference

20 December 2017

11

Tetsutaro Sata

1 reference

20 December 2017

Takeshi Kurata

9

object named as

Takeshi Kurata

1 reference

20 December 2017

author name string

Masanobu Kinomoto

1

1 reference

20 December 2017

Regina Appiah-Opong

2

1 reference

20 December 2017

J A M Brandful

3

1 reference

20 December 2017

Masaru Yokoyama

4

1 reference

20 December 2017

Nicholas Nii-Trebi

5

1 reference

20 December 2017

Evelyn Ugly-Kwame

6

1 reference

20 December 2017

Hironori Sato

7

1 reference

20 December 2017

Kinomoto, M.

0 references

Appiah-Opong, R.

0 references

Brandful, J.A.M.

0 references

Yokoyama, M.

0 references

Nii-Trebi, N.

0 references

Ugly-Kwame, E.

0 references

Sato, H.

0 references

Ofori-Adjei, D.

0 references

Kurata, T.

0 references

Barre-Sinoussi, F.

0 references

Sata, T.

0 references

Tokunaga, K.

0 references

language of work or name

English

0 references

publication date

8 June 2005

1 reference

20 December 2017

Clinical Infectious Diseases

2005

0 references

published in

1 reference

20 December 2017

volume

41

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

243-251

1 reference

20 December 2017

Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants

cites work

1 reference

Near full-length genome analysis of HIV type 1 CRF02.AG subtype C and CRF02.AG subtype G recombinants

21 January 2018

1 reference

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

21 January 2018

1 reference

Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population

21 January 2018

1 reference

Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.

21 January 2018

1 reference

Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon

21 January 2018

1 reference

Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale

21 January 2018

1 reference

Presence of Key Drug Resistance Mutations in Isolates from Untreated Patients of Abidjan, Côte d'Ivoire: ANRS 1257 Study

21 January 2018

1 reference

HIV Type 1 Diversity in France, 1999–2001: Molecular Characterization of non-B HIV Type 1 Subtypes and Potential Impact on Susceptibility to Antiretroviral Drugs

21 January 2018

1 reference

Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes

21 January 2018

1 reference

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire

21 January 2018

1 reference

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients

21 January 2018

1 reference

Drug resistance in non-subtype B HIV-1.

21 January 2018

1 reference

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy

21 January 2018

1 reference

Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy

21 January 2018

1 reference

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

21 January 2018

1 reference

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study

21 January 2018

1 reference

Infectious DNA clone of HIV type 1 A/G recombinant (CRF02_AG) replicable in peripheral blood mononuclear cells

21 January 2018

1 reference

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

21 January 2018

1 reference

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

21 January 2018

1 reference

Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.

21 January 2018

1 reference

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

21 January 2018

1 reference

An infectious DNA clone of HIV type 1 subtype C.

21 January 2018

1 reference

Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents

21 January 2018

1 reference

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

21 January 2018

1 reference

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor

21 January 2018

1 reference

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro

21 January 2018

1 reference

Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication

21 January 2018

1 reference

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

Low-dose ritonavir moderately enhances nelfinavir exposure

21 January 2018

1 reference

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

21 January 2018

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1086/431197

pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1086/431197

Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1086/431197

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1086/431197

Identifiers

DOI

10.1086/431197

1 reference

20 December 2017

1 reference

20 December 2017